Our Comment:
Despite its hazards, amitriptyline can still be considered as one of the most important pillars of antidepressant treatment. For no other tri- or tetracyclic antidepressant agent (including lofepramine and maprotiline) has the efficiency or tolerance been better documented. Neither the selective serotonin re-uptake inhibitors (e.g. fluoxetine) nor the MAO inhibitor modobemid are said to have a more favourable use/risk ratio; however, this has yet to be proven.